Brief: Argenx Reports $2.2 Bln FY Preliminary Global Product Net Sales

argenx SE

13/01/2025 06:06

Jan 13 (Reuters) - argenx SE  ARGX.BR :
    * ARGENX HIGHLIGHTS 2025 STRATEGIC PRIORITIES
    * REPORTS $2.2 BILLION IN PRELIMINARY 2024 GLOBAL PRODUCT
NET
SALES
    * 10 ONGOING REGISTRATIONAL STUDIES IN 2025 ACROSS
EFGARTIGIMOD
AND EMPASIPRUBART
    * ESTABLISHES 'VISION 2030' FOR LONG-TERM GROWTH
    * AIMS TO TREAT 50,000 PATIENTS GLOBALLY BY 2030
    * HAD APPROXIMATELY $3.4 BILLION IN CASH AS OF DEC 31, 2024
    * EXPECTS COMBINED RESEARCH AND DEVELOPMENT AND SG&A
EXPENSES IN
2025 TO BE $2.5 BILLION
    * CONTINUES INVESTMENT IN IMMUNOLOGY INNOVATION PROGRAM
    * EXPECTS TRANSITION TO SUSTAINABLE PROFITABILITY IN 2025

Source text:  urn:newsml:reuters.com:*:nGNX5xzzJK
Further company coverage:  ARGX.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))